View clinical trials related to Glioma.
Filter by:To advance understanding of environmental, behavioral and genetic causes of brain tumors in adults, DCEG investigators initiated a multicenter case-control study of malignant and benign tumors in adults in 1994. This four-year study was conducted at participating hospitals in Boston, Phoenix, and Pittsburgh. Eligible cases were individuals greater than or equal to 18 years newly diagnosed with an intracranial glioma, meningioma or acoustic neuroma and treated at one of the participating hospitals. The controls were patients admitted to neurological, neurosurgical or general surgical services at the same three hospitals for any of a variety of non-neoplastic conditions. By the end of the study, 811 brain tumor cases had been accrued. Information about a broad range of possible environmental, lifestyle, and genetic risk factors was obtained from both cases and controls through a computer-assisted personal interview (CAPI). The family history component obtained history and age at diagnosis of cancer or benign brain tumors and selected other diseases, for all living and deceased first degree relatives. A supplemental self-administered questionnaire covered diet, vitamin supplements, alcohol consumption, and household use of electrical appliances. Blood samples were obtained as a source of DNA. Currently, data analysis is in the early stages. To increase our ability to examine both genetic and environmental components of brain tumor risk, we decided to add a family studies component to the case-control study, focusing on families of glioma cases. Initial contact with each family is made through the cases or, if a case is deceased, through the next of kin. Cases or next of kin are asked to complete a Family Health Questionnaire that updates the family medical history and provides contacting information for all adult first degree relatives and more distant relatives with cancer. Then, we contact all first degree relatives greater than or equal to age 18 years, and the next of kin of deceased eligible relatives and invite them to complete a modified risk factor interview conducted over the telephone. This interview obtains information about each relative s personal and family history of cancer and other diseases, and history of risk factor exposures, including all the major categories covered in the case-control study. Study participants who complete the interview are then asked to provide buccal cells as a source of DNA for future genotyping. The glioma cases and their relatives will serve as a unique resource for both epidemiologic and genetic analyses. Selected relatives can serve as controls for association thereby eliminating concerns and population stratification. The study design also permits assessment of specific genetic hypotheses that cannot be evaluated in a traditional case-control study. Data from all first degree relatives of the glioma cases will be used in association studies and segregation analysis. In addition, we can screen DNA from members of multiplex families (families with 2 or more relatives with a primary CNS tumor) for mutations in candidate genes known to be associated with glioma, and contribute data from selected multiplex families to collaborative linkage studies to search for new genes conferring susceptibility to brain and possibly related tumors.
The purpose of this study was to determine the maximum tolerated dose (MTD) and the recommended dose for future studies of ECO-4601 administered as a continuous IV infusion for 14 days with 7 days recovery (21 day cycle) in patients with histologically confirmed solid tumors (high grade glioma, colorectal, lung, breast, ovarian, pancreatic and prostate). This study was also designed to determine the clinical pharmacokinetic profile, safety of multiple cycles of administration, and document the antitumor activity of ECO-4601.
This phase I trial is studying the side effects and best dose of AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with supratentorial low-grade glioma.
This phase I/II trial studies the side effects and best dose of melphalan when given together with carboplatin, etoposide phosphate, mannitol, and sodium thiosulfate and to see how well they work in treating patients with previously treated brain tumors. Drugs used in chemotherapy, such as melphalan, carboplatin, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption (BBBD) uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Sodium thiosulfate may help lessen or prevent hearing loss and toxicities in patients undergoing chemotherapy with carboplatin and BBBD. Giving carboplatin, melphalan, etoposide phosphate, mannitol, and sodium thiosulfate together may be an effective treatment for brain tumors.
This study will examine the use of a variation of standard magnetic resonance imaging (MRI) called diffusion tensor MRI (DT-MRI) for distinguishing injured brain tissue due to radiation therapy (radiation necrosis) from the return of a brain tumor that was previously removed (tumor recurrence). DT-MRI differs from standard MRI in the way that computers process the images; there is no difference in the experience of having the procedure done. Both radiation necrosis and tumor recurrence can occur within weeks to months following brain radiation treatment. Because the treatment and management options for the two conditions differ significantly, distinguishing the two is of critical importance. Currently, surgical biopsy is required to make this differentiation. Healthy volunteers and patients who have received radiation therapy as part of their treatment for a brain tumor may be eligible for this study. All candidates must be at least 21 years old. Patients must have a new area of abnormality that requires a biopsy to determine whether it is a tumor recurrence or radiation necrosis. Candidates are screened with a medical history and physical examination. In addition, patients have blood and urine tests. All participants undergo MRI and DT-MRI. MRI uses a strong magnetic field and radio waves instead of X-rays to obtain images of body organs and tissues. The MRI scanner is a metal cylinder surrounded by a strong magnetic field. During the MRI, the subject lies on a table that can slide in and out of the cylinder and wears earplugs to muffle loud knocking noises that occur during the scanning. Scanning time varies from 20 minutes to 3 hours, with most scans lasting 40-60 minutes. Subjects may be asked to lie still for up to 20 minutes at a time. DT-MRI is a type of MRI that measures how water moves in the brain tissue. This technique uses the same MRI machine as conventional MRI, but the diffusion images are obtained after the normal MRI scan, and by a computer program that is installed into the machine. This completes the participation of healthy subjects. In addition to the scans, patients undergo brain biopsy of the abnormal areas identified by MRI. Patients' commitment to the study protocol is fulfilled when the surgery is complete; they may, however, continue to receive follow-up care at the NIH Clinical Center after they complete the study. They are given the results of the biopsy so that further treatment, if necessary, can be arranged.
To establish a clinic based case control study for examination of potential risk factors for primary adult brain tumors.
The purpose of this study is to compare the response to treatment and side effects associated with high dose irinotecan in patients with recurrent brain tumors.
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying giving radiation therapy or combination chemotherapy to see how well it works in treating patients with clinically or radiologically progressive low-grade gliomas.
This phase II trial is studying how well giving O6-benzylguanine together with temozolomide works in treating young patients with recurrent or progressive gliomas or brain stem tumors. Drugs used in chemotherapy, such as O6-benzylguanine and temozolomide , work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. O6-benzylguanine may help temozolomide work better by making tumor cells more sensitive to the drug. Giving more than one drug (combination chemotherapy) may kill more tumor cells.